Screener
Cytokinetics CYTK EBIT
EBIT at other companies
Other financials
Where this comes from
Calculated from Cytokinetics’s reported figures.
Plus components not separately reported this period.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
FAQ
- What is Cytokinetics's EBIT?
- Cytokinetics (CYTK) reported EBIT of -$179.17M in Q2 2026.
- How has Cytokinetics's EBIT changed year-over-year?
- Cytokinetics's EBIT decreased by 60.7% year-over-year, from -$111.51M to -$179.17M.
- What is the long-term trend for Cytokinetics's EBIT?
- Over 4 years (2021 to 2025), Cytokinetics's EBIT has grown at a 34.6% compound annual growth rate (CAGR), from -$186.31M to -$612.26M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Cytokinetics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude